Skip to main menu | Skip to main content
us-flag  United States | Apotex Worldwide 
For Media Inquiries, Please Contact:

Jordan Berman
Vice President,
Global Corporate Communications

Apotex Inc.
  1 (416) 749-9026 Ext. 7487
   Email

Press Center

Sep 25, 2019
Apotex Corp. Issues Voluntary Nationwide Recall of Ranitidine Tablets 75mg and 150mg (All pack sizes and Formats) due to the potential for Detection of an Amount of Unexpected Impurity,N-nitrosodimethylamine (NDMA) Impurity in the product

FOR IMMEDIATE RELEASE – September 25, 2019 – Weston, Florida, Apotex Corp. is voluntarily, on a precautionary basis, recalling Ranitidine Tablets 75mg and 150mg (All pack sizes and Formats) to the Retail level. Apotex has learned from the U.S. Food and Drug Administration and other Global regulators that some ranitidine medicines including brand and generic formulations of ranitidine regardless of the manufacturer, contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. To date, Apotex has not received any reports of adverse events related to use of the product.

Risk Statement: NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.

Ranitidine Hydrochloride Tablet is an over the counter (OTC) oral product indicated for the relief of heartburn associated with acid indigestion and sour stomach and prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages. The affected Ranitidine Hydrochloride Tablets can be identified by NDC numbers stated on the product label.  

 

Product

Strength

Pack Size

NDC Number

Ranitidine tablets, USP 150mg- acid reducer (Rite Aid)

150 mg

50's Bottle

11822-6052-1

Ranitidine tablets, USP 150mg- acid reducer (Rite Aid)

150 mg

65's Bottle

11822-6052-2

Ranitidine tablets, USP 150mg- acid reducer (Rite Aid)

150 mg

95's Bottle

11822-4727-3

Ranitidine tablets, USP 150mg- acid reducer (Walmart)

150 mg

65's Bottle

49035-117-06

Ranitidine tablets, USP 150mg- acid reducer (Walmart)

150 mg

24's Bottle

49035-100-00

Wal-Zan® 150 RANITIDINE TABLETS, USP 150 mg / ACID REDUCER (WALGREENS)

150 mg

200's Bottle

0363-1030-07

 

Product

Strength

Pack Size

NDC Number

Ranitidine tablets, USP 150 mg - acid reducer (Rite Aid)

150 mg

24's Bottle

11822-6051-8

Ranitidine tablets, USP 150mg- acid reducer (Walmart)

150 mg

130's Bottle

49035-100-07

Wal-Zan® 150 RANITIDINE TABLETS, USP 150 mg / ACID REDUCER (WALGREENS)

150 mg

24's Bottle

0363-1013-02

Wal-Zan® 75 RANITIDINE TABLETS, USP 75 mg / ACID REDUCER (WALGREENS)

75 mg

30's Bottle

0363-1029-03

Cool mint Ranitidine tablets, USP 150 mg - acid reducer (Rite Aid)

150 mg

24's Bottle

11822-6107-4

Wal-Zan® 150 RANITIDINE TABLETS, USP 150 mg / ACID REDUCER (WALGREENS)

150 mg

65's Bottle

0363-1030-06

Wal-Zan® 150 RANITIDINE TABLETS, USP 150 mg / ACID REDUCER (WALGREENS)

150 mg

95's Bottle

0363-1030-09

 

The affected Ranitidine Hydrochloride Tablets were distributed Nationwide to Warehousing Chains. Apotex Corp.  has notified its affected direct account Warehousing Chains via mail (FedEx Standard Overnight) by mailing a recall notification letter and is arranging for return of all recalled product.

Wholesalers, Distributors and Retailers return the impacted product to place of purchase. Anyone with an existing inventory of the product should quarantine the recalled lots immediately.  Customers who purchased the impacted product directly from Apotex can call Inmar Rx Solutions at 800-967-5952 (option 1) (9:00am – 5:00-pm, EST Monday thru Friday), to arrange for their return.

Consumers with questions regarding this recall can contact Apotex corp.  by phone-number 1-800-706-5575 (8:30am – 5:00pm, EST Monday thru Friday) or email address UScustomerservice@Apotex.com. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

- 30 -

Media Contact:
Jordan Berman, Vice President, Global Corporate Communications
Tel:  1 (416) 749-9026 Ext. 7487
E-Mail:  jberman@apotex.com